PGL 0.00% 44.0¢ prospa group limited.

bell potter research

  1. 229 Posts.
    Industry news implies changes to commercialisation strategies highly relevant to
    PGL
    We attended the annual BIO conference held in Boston MA USA last week. More than
    20,000 industry professionals attended this year’s international convention with
    presentations by a panel of experts from the industry including some of the finest thoughtleaders,
    CEOs and other top executives. Three of the numerous presentations we attended
    were highly relevant to PGL and we remain confident the company is on the right track to
    commercialising its lead drug, PI-88.
    Global biotech partnering trends indicate PGL retaining maximum possible value of
    PI-88
    The forecast for 2007-08 for international biotech deals points towards either very earlystage
    deals or co-development at the later stage of development. This trend has largely
    occurred because smaller biotechs are retaining significant control over the development of
    their drug as well as much of the value. PGL is a clear case in point here and it seems that
    its international peers are following the same path. Consequently, pharma companies have
    been forced to become more flexible in their negotiations.
    Adopting new and innovative clinical trial designs to speed up development
    There is a trend towards creating new trial designs and clinical development programs that
    will accelerate clinical trials, improve the probability of a drug’s success, reduce costs and
    increase safety for patients. We believe PGL may consider adopting a new approach
    involving the drug:placebo ration which would further accelerate the development of PI-88.
    Buy 2 rating maintained based on $14.64 probability-weighted valuation
    Whilst we remain disappointed with the heavy discount placed on the issue price in the
    recent $74m capital raising, we maintain our Buy 2 rating. The various presentations we
    attended at the recent BIO conference all point to PGL behaving like a successful global
    biotech company. Our DCF probability-weighted valuation remains unchanged at $14.64.
    We remain confident that this valuation gap will narrow over the next 6-12 months as PGL
    embarks on the final stage of its commercialisation of PI-88.
    INVESTMENT DATA
    Share Price $5.86
    Issued Capital
    Ordinary Shares 59.3m
    Options 0.6m
    Fully Diluted 59.9m
    Market Capitalisation $351.0m
    52 Week Low/High $2.52 / $9.49
    Valuation $14.64
    Top 20 shareholders as at 30 June 2006 own
    63% of total shares on issue
    Year end Jun 06a 07f 08f 09f
    Revenue $m 1.7 0.9 0.0 0.0
    EBITDA $m -8.7 -16.9 -43.9 -38.2
    NPAT $m -7.6 -16.8 -39.5 -35.8
    EPS (adj) ¢ -18.8 -38.4 -90.7 -82.0
    EPS growth % na na na na
    PER x na na na na
    Data is normalised and fully diluted.
    Progen Pharmaceuticals (PGL) Buy 2
 
watchlist Created with Sketch. Add PGL (ASX) to my watchlist
(20min delay)
Last
44.0¢
Change
0.000(0.00%)
Mkt cap ! $72.46M
Open High Low Value Volume
44.0¢ 44.0¢ 44.0¢ $53.59K 121.8K

Buyers (Bids)

No. Vol. Price($)
4 402845 44.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.5¢ 97049 5
View Market Depth
Last trade - 11.46am 03/07/2024 (20 minute delay) ?
PGL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.